Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 2
1985 1
1988 1
1990 1
1992 1
1993 1
1994 1
2006 1
2007 2
2008 2
2010 1
2011 2
2014 3
2015 2
2016 2
2017 1
2019 1
2020 2
2021 1
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.
Al-Kali A, Aldoss I, Atherton PJ, Strand CA, Shah B, Webster J, Bhatnagar B, Flatten KS, Peterson KL, Schneider PA, Buhrow SA, Kong J, Reid JM, Adjei AA, Kaufmann SH. Al-Kali A, et al. Among authors: buhrow sa. Cancer Med. 2023 Dec;12(23):21229-21239. doi: 10.1002/cam4.6701. Epub 2023 Nov 13. Cancer Med. 2023. PMID: 37960985 Free PMC article. Clinical Trial.
Chondrocytic and pharmacokinetic properties of Phlpp inhibitors.
Taylor EL, Weaver SR, Zars EL, Turner CA, Buhrow SA, Reid JM, Bradley EW, Westendorf JJ. Taylor EL, et al. Among authors: buhrow sa. Osteoarthr Cartil Open. 2021 Jun 8;3(3):100190. doi: 10.1016/j.ocarto.2021.100190. eCollection 2021 Sep. Osteoarthr Cartil Open. 2021. PMID: 36474816 Free PMC article.
Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid Tumors.
Koubek EJ, Ralya AT, Larson TR, McGovern RM, Buhrow SA, Covey JM, Adjei AA, Takebe N, Ames MM, Goetz MP, Reid JM. Koubek EJ, et al. Among authors: buhrow sa. J Clin Pharmacol. 2022 Sep;62(9):1121-1131. doi: 10.1002/jcph.2053. Epub 2022 Apr 19. J Clin Pharmacol. 2022. PMID: 35358345 Free PMC article.
Antibody-Targeted Chemotherapy for the Treatment of Melanoma.
Nevala WK, Buhrow SA, Knauer DJ, Reid JM, Atanasova EA, Markovic SN. Nevala WK, et al. Among authors: buhrow sa. Cancer Res. 2016 Jul 1;76(13):3954-64. doi: 10.1158/0008-5472.CAN-15-3131. Epub 2016 Apr 28. Cancer Res. 2016. PMID: 27197186
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
Jayaraman S, Hou X, Kuffel MJ, Suman VJ, Hoskin TL, Reinicke KE, Monroe DG, Kalari KR, Tang X, Zeldenrust MA, Cheng J, Bruinsma ES, Buhrow SA, McGovern RM, Safgren SL, Walden CA, Carter JM, Reid JM, Ingle JN, Ames MM, Hawse JR, Goetz MP. Jayaraman S, et al. Among authors: buhrow sa. Breast Cancer Res. 2020 May 19;22(1):51. doi: 10.1186/s13058-020-01286-7. Breast Cancer Res. 2020. PMID: 32430040 Free PMC article.
A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.
Kalogera E, Nevala WK, Finnes HD, Suman VJ, Schimke JM, Strand CA, Kottschade LA, Kudgus RA, Buhrow SA, Becher LR, Geng L, Glaser GE, Grudem ME, Jatoi A, Klampe CM, Kumar A, Langstraat CL, McWilliams RR, Wahner Hendrickson AE, Weroha SJ, Yan Y, Reid JM, Markovic SN, Block MS. Kalogera E, et al. Among authors: buhrow sa. Clin Cancer Res. 2024 Mar 26. doi: 10.1158/1078-0432.CCR-23-3196. Online ahead of print. Clin Cancer Res. 2024. PMID: 38530846
32 results